Teladoc Health stock launches new AI tools for hospitals

Published on 10/08/2026 at 02:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Teladoc Health stock adds SoloVitals and SoloScribe for hospitals on October 7, 2026. Solo spans 15,000 care locations, while Q2 revenue fell 4 percent to USD 606.9 million.

TDOC, US87918A1051, Illustration mit AI erstellt.

Teladoc Health (ISIN US87918A1051) was last at USD 5.56 on the NYSE on October 7, 2026, at 4:00 p.m. ET, down 3.64 percent from the previous close. The company introduced two artificial intelligence tools for hospitals and health systems on October 7, giving the stock a fresh product catalyst as its core business works through weaker mental health revenue.

AI tools target hospital workflows

According to GlobeNewswire, SoloVitals measures heart rate and respiration through a camera-equipped smartphone or tablet, while SoloScribe creates structured clinical notes for electronic health records.

The release said Solo is installed in more than 15,000 care locations globally. SoloScribe is generally available, while SoloVitals is in private preview for select customers and is scheduled for broader release in December 2026.

Q2 revenue fell 4 percent

Teladoc's second-quarter 2026 results show why the platform expansion matters. Zacks reported adjusted EPS of negative USD 0.21 for Q2 2026 versus a consensus loss of USD 0.24, while revenue declined 4 percent year over year to USD 606.9 million.

The split between businesses was material. Integrated Care revenue increased 1 percent year over year to USD 394.3 million and produced a 16.5 percent adjusted EBITDA margin, while BetterHelp revenue fell 12 percent to USD 212.6 million, according to Zacks.

Teladoc's 2026 revenue guidance stands at USD 2.362 billion to USD 2.447 billion, down from the earlier USD 2.481 billion to USD 2.576 billion range. The lower outlook keeps BetterHelp execution central to the stock story even as the enterprise platform adds new AI functionality.

Analyst target stays above USD 5.56

Simply Wall St's page updated October 5 lists an average price target of USD 7.70 from 22 analysts. That target lies 38.5 percent above the USD 5.56 reference price, a numerical gap that contrasts with the company's 4 percent Q2 revenue decline.

Teladoc's next reported checkpoint is October 28, 2026, after the market closes. MarketBeat lists expected Q3 revenue of USD 588.45 million and consensus EPS of negative USD 0.22 for that report.

TDOC remains below its yearly high

TDOC was last at USD 5.56 on the NYSE on October 7, 2026, with an intraday range of USD 5.53 to USD 5.76. Its 52-week range was USD 4.40 to USD 9.89, and market capitalization stood at USD 1.0 billion as of October 7, 2026.